Comerica Bank Sells 11,176 Shares of Zoetis Inc. $ZTS

Comerica Bank lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 192,939 shares of the company’s stock after selling 11,176 shares during the quarter. Comerica Bank’s holdings in Zoetis were worth $31,767,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. Cornerstone Planning Group LLC raised its stake in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after acquiring an additional 120 shares in the last quarter. Sound Income Strategies LLC raised its stake in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company’s stock worth $46,000 after acquiring an additional 164 shares in the last quarter. Finally, Bfsg LLC raised its stake in shares of Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company’s stock worth $48,000 after acquiring an additional 252 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $202.43.

Zoetis Stock Up 0.5%

NYSE:ZTS opened at $156.3180 on Monday. The company’s 50 day moving average is $153.84 and its two-hundred day moving average is $158.41. The company has a market cap of $69.28 billion, a PE ratio of 26.91, a P/E/G ratio of 2.51 and a beta of 0.88. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company’s stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.